Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: Results of the Korean Multiple Myeloma Working Party (KMMWP)

Annals of Hematology

Volumn 89, Issue 5, 2010, Pages 489-497

  Eom, Hyeon Seok ^a   Kim, Yeo Kyeoung ^b   Chung, Joo Seop ^c   Kim, Kihyun ^d   Kim, Hyo Jung ^e   Kim, Ho Young ^e   Jin, Jong Youl ^f   Do, Young Rok ^g   Oh, Suk Joong ^d   Suh, Cheolwon ^h   Seong, Chu Myong ⁱ   Kim, Chul Soo ^j   Lee, Dong Soon ^k   Lee, Jae Hoon ^l  

^a National Cancer Center   (South Korea)

^b Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^c Pusan National University Hospital   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Hallym University Medical Center   (South Korea)

^f Holy Family Hospital   (South Korea)

^g Dongsan Medical Center   (South Korea)

^h University of Ulsan College of Medicine   (South Korea)

ⁱ Ewha Womans University   (South Korea)

^j Inha University Hospital   (South Korea)

^k Seoul National University Hospital   (South Korea)

^l Gachon University College of Medicine   (South Korea)

more..

Author keywords

Bortezomib; Elderly patients; High risk; Multiple myeloma; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYTOGENETICS; DEEP VEIN THROMBOSIS; DELIRIUM; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEART EJECTION FRACTION; HERPES ZOSTER; HUMAN; HYPOXIA; INFECTION; LEUKOPENIA; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEURALGIA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TREMOR; VOMITING; WEAKNESS; ADJUVANT THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KOREA; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KOREA; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOADJUVANT THERAPY; PREDNISOLONE; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77950584870     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0871-y     Document Type: Article

References (31)

1. M Attal JL Harousseau AM Stoppa, et al. 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 91 97 10.1056/NEJM199607113350204 1:STN:280:DyaK283ms1emuw%3D%3D 8649495 (Pubitemid 26240110)
2. JA Child GJ Morgan FE Davies, et al. 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 1875 1883 10.1056/NEJMoa022340 1:CAS:528:DC%2BD3sXjsVChtLo%3D 12736280 (Pubitemid 36532313)
3. BK Edwards ML Brown PA Wingo, et al. 2005 Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment J Natl Cancer Inst 97 1407 1427 16204691
4. B Barlogie E Anaissie F van Rhee, et al. 2007 Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 Br J Haematol 138 176 185 10.1111/j.1365-2141.2007.06639.x 1:CAS:528: DC%2BD2sXptFGgtLk%3D 17593024 (Pubitemid 46978271)
5. M Pineda-Roman M Zangari F van Rhee, et al. 2008 VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma Leukemia 22 1419 1427 10.1038/leu.2008.99 1:CAS:528:DC%2BD1cXosFSms78%3D 18432260 (Pubitemid 352006086)
6. A Palumbo S Bringhen T Caravita, et al. 2006 Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet 367 825 831 10.1016/S0140-6736(06)68338-4 1:CAS:528:DC%2BD28Xit1eht7c%3D 16530576 (Pubitemid 43363369)
7. T Facon JY Mary C Hulin, et al. 2007 Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet 370 1209 1218 10.1016/S0140-6736(07) 61537-2 1:CAS:528:DC%2BD2sXhtFehsr%2FN 17920916 (Pubitemid 47516593)
8. A Palumbo S Bringhen AM Liberati, et al. 2008 Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial Blood 112 3107 3114 10.1182/blood-2008-04-149427 1:CAS:528:DC%2BD1cXht1Omur7P 18505783
9. WJ Chng R Fonseca 2005 Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics Clin Lymphoma Myeloma 6 200 207 10.3816/CLM.2005.n.047 16354325
10. R Fonseca B Barlogie R Bataille, et al. 2004 Genetics and cytogenetics of multiple myeloma: a workshop report Cancer Res 64 1546 1558 10.1158/0008-5472.CAN-03-2876 1:CAS:528:DC%2BD2cXhtleitb4%3D 14989251 (Pubitemid 38235629)
11. AK Stewart R Fonseca 2005 Prognostic and therapeutic significance of myeloma genetics and gene expression profiling J Clin Oncol 23 6339 6344 10.1200/JCO.2005.05.023 1:CAS:528:DC%2BD2MXhtFWntbnF 16155017 (Pubitemid 46218844)
12. PG Richardson H Briemberg S Jagannath, et al. 2006 Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib J Clin Oncol 24 3113 3120 10.1200/JCO.2005.04.7779 1:CAS:528:DC%2BD28XnslKhs7c%3D 16754936 (Pubitemid 46638949)
13. J Blade D Samson D Reece, et al. 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant Br J Haematol 102 1115 1123 10.1046/j.1365-2141.1998.00930.x 1:STN:280:DyaK1cvitl2mtw%3D%3D 9753033 (Pubitemid 28435189)
14. Rooney DE, Czepalkowski BH (1992) Human cytogenetics, a practical approach. Oxford University Press, New York
15. Mitelman F (1995) An international system for human cytogenetic nomenclature (1995); Recommendations of the international standing committee on human cytogenetic nomenclature, Memphis, Tennessee, USA, October 9-13, 1994. S. Karger AG, Basel
16. MA Gertz MQ Lacy A Dispenzieri, et al. 2005 Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy Blood 106 2837 2840 10.1182/blood-2005-04-1411 1:CAS:528:DC%2BD2MXhtFantbbJ 15976175 (Pubitemid 41510761)
17. JR Sawyer JA Waldron S Jagannath, et al. 1995 Cytogenetic findings in 200 patients with multiple myeloma Cancer Genet Cytogenet 82 41 49 10.1016/0165-4608(94)00284-I 1:STN:280:DyaK2MzlsVWitg%3D%3D 7627933
18. L Chiecchio RK Protheroe AH Ibrahim, et al. 2006 Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma Leukemia 20 1610 1617 10.1038/sj.leu.2404304 1:CAS:528: DC%2BD28XosVSjs7o%3D 16826223 (Pubitemid 44264105)
19. PG Richardson B Barlogie J Berenson, et al. 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609 2617 10.1056/NEJMoa030288 1:CAS:528:DC%2BD3sXkvVSksLs%3D 12826635 (Pubitemid 36741588)
20. JR Berenson S Jagannath B Barlogie, et al. 2005 Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma Cancer 104 2141 2148 10.1002/cncr.21427 1:CAS:528:DC%2BD2MXht1Clu7fE 16206291 (Pubitemid 41579960)
21. S Singhal J Mehta R Desikan, et al. 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1565 1571 10.1056/NEJM199911183412102 1:CAS:528:DyaK1MXotVSgs78%3D 10564685
22. A Palumbo A Bertola P Musto, et al. 2005 Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma Cancer 104 1428 1433 10.1002/cncr.21342 1:CAS:528:DC%2BD2MXhtFahsb%2FP 16116606 (Pubitemid 41356158)
23. A Badros O Goloubeva JS Dalal, et al. 2007 Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature Cancer 110 1042 1049 10.1002/cncr.22921 1:CAS:528:DC%2BD2sXhtVChs7fP 17654660 (Pubitemid 47312870)
24. AA Argyriou G Iconomou HP Kalofonos 2008 Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature Blood 112 1593 1599 10.1182/blood-2008-04-149385 1:CAS:528:DC%2BD1cXhtVylurfJ 18574024
25. S Jagannath B Barlogie J Berenson, et al. 2004 A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 165 172 10.1111/j.1365-2141.2004.05188.x 1:CAS:528:DC%2BD2cXpvFait7g%3D 15461622 (Pubitemid 39371809)
26. PG Richardson P Sonneveld MW Schuster, et al. 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487 2498 10.1056/NEJMoa043445 1:CAS:528:DC%2BD2MXltlaksLc%3D 15958804 (Pubitemid 41007864)
27. Palumbo A, Bringhen S, Rossi D et al (2008) A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood 112. Abstract 652
28. MV Mateos JM Hernandez MT Hernandez, et al. 2006 Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study Blood 108 2165 2172 10.1182/blood-2006-04-019778 1:CAS:528:DC%2BD28XhtVCgtbfI 16772605 (Pubitemid 44497496)
29. PG Richardson P Sonneveld MW Schuster, et al. 2009 Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline Br J Haematol 144 895 903 10.1111/j.1365-2141.2008.07573.x 1:CAS:528: DC%2BD1MXkt12ntbw%3D 19170677
30. H Chang XY Qi S Samiee, et al. 2005 Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation Bone Marrow Transplant 36 793 796 10.1038/sj.bmt.1705131 1:CAS:528: DC%2BD2MXhtFWjsr3F 16113669 (Pubitemid 41613302)
31. Y Inamoto S Kurahashi N Imahashi, et al. 2009 Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation Am J Hematol 84 283 286 10.1002/ajh.21390 19338045